Human Cancers Express TRAILshort, a Dominant Negative TRAIL Splice Variant, Which Impairs Immune Effector Cell Killing of Tumor Cells
- 14 July 2020
- journal article
- research article
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 26 (21), 5759-5771
- https://doi.org/10.1158/1078-0432.CCR-20-0251
Abstract
Purpose: TNF-related apoptosis inducing ligand (TRAIL) expression by immune cells contributes to antitumor immunity. A naturally occurring splice variant of TRAIL, called TRAILshort, antagonizes TRAIL-dependent cell killing. It is unknown whether tumor cells express TRAILshort and if it impacts antitumor immunity. Experimental Design: We used an unbiased informatics approach to identify TRAILshort expression in primary human cancers, and validated those results with IHC and ISH. TRAILshort-specific mAbs were used to determine the effect of TRAILshort on tumor cell sensitivity to TRAIL, and to immune effector cell dependent killing of autologous primary tumors. Results: As many as 40% of primary human tumors express TRAILshort by both RNA sequencing and IHC analysis. By ISH, TRAILshort expression is present in tumor cells and not bystander cells. TRAILshort inhibition enhances cancer cell lines sensitivity to TRAIL-dependent killing both in vitro and in immunodeficient xenograftmouse models. Immune effector cells isolated from patients with B-cellmalignancies killedmore autologous tumor cells in the presence compared with the absence of TRAILshort antibody (P < 0.05). Conclusions: These results identify TRAILshort in primary human malignancies, and suggest that TRAILshort blockade can augment the effector function of autologous immune effector cells.Keywords
Other Versions
Funding Information
- NIAID (AI110173, AI120698)
- NCI (P50CA97274, P50CA102701)
This publication has 49 references indexed in Scilit:
- The Cancer Genome Atlas Pan-Cancer analysis projectNature Genetics, 2013
- Bioluminescence imaging of leukemia cell lines in vitro and in mouse xenografts: effects of monoclonal and polyclonal cell populations on intensity and kinetics of photon emissionJournal of Hematology & Oncology, 2013
- MALT1 Small Molecule Inhibitors Specifically Suppress ABC-DLBCL In Vitro and In VivoCancer Cell, 2012
- Isolation of a TRAIL Antagonist from the Serum of HIV-infected Patients*Journal of Biological Chemistry, 2011
- Cyclophosphamide Chemotherapy Sensitizes Tumor Cells to TRAIL-Dependent CD8 T Cell-Mediated Immune Attack Resulting in Suppression of Tumor GrowthPLOS ONE, 2009
- TRAIL-R deficiency in mice promotes susceptibility to chronic inflammation and tumorigenesisJCI Insight, 2008
- TRAIL induced survival and proliferation in cancer cells resistant towards TRAIL-induced apoptosis mediated by NF-κBOncogene, 2003
- Critical Role for Tumor Necrosis Factor–related Apoptosis-inducing Ligand in Immune Surveillance Against Tumor DevelopmentThe Journal of Experimental Medicine, 2002
- Initial sequencing and analysis of the human genomeNature, 2001
- TRAIL/Apo-2-ligand-induced apoptosis in human T cellsEuropean Journal of Immunology, 1998